Association between patient age and gabapentin serum concentration-to-dose ratio: A preliminary multivariate analysis

Therapeutic Drug Monitoring

Volumn 26, Issue 6, 2004, Pages 633-637

  Armijo, Juan A ^a   Pena, Maria A ^a   Adín, Javier ^a   Vega Gil, Noelia ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Age influence; Antiepileptic drugs; Concentration to dose ratio; Dosage influence; Epilepsy; Gabapentin; Therapeutic drug monitoring

Indexed keywords

ANTICONVULSIVE AGENT; GABAPENTIN;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; BODY WEIGHT; CHILD; CORRELATION ANALYSIS; COVARIANCE; DRUG BLOOD LEVEL; EPILEPSY; FEMALE; FOCAL EPILEPSY; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; NEUROPATHIC PAIN; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; AGING; AMINES; ANALYSIS OF VARIANCE; CHILD; CHILD, PRESCHOOL; CYCLOHEXANECARBOXYLIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES;

EID: 9644276759     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200412000-00008     Document Type: Article

References (18)

1. Dougherty JA, Rhoney DH. Gabapentin: a unique anti-epileptic agent. Neurol Res. 2001;23:821-829.
2. Pippenger CE. Pediatric clinical pharmacology of antiepileptic drugs: an especial consideration. In: Pippenger CE, Penry JK, Kutt H, eds. Antiepileptic Drugs: Quantitative Analysis and Interpretation. New York: Raven Press; 1978:315-319.
3. Goa KL, Sorkin EM. Gabapentin. A review of its pharmacological properties and of its potential in epilepsy. Drugs. 1993;46:409-427.
4. McLean MJ. Gabapentin. Epilepsia. 1995;36(Suppl 2):73-86.
5. Allen E, Tsanaclis LM, Wroe SJ, et al. Gabapentin does not affect antipyrine clearance. J Clin Pharmacol. 1999;39:934-935.
6. Blum RA, Comstock TJ, Sica DA, et al. Pharmacokinetics of gabapentin in subjects with various degrees of renal function. Clin Pharmacol Ther. 1994;56:154-159.
7. Hachad H, Ragueneau-Majlessi I, Levy RH. New antiepileptic drugs: Review on drug interactions. Ther Drug Monit. 2002;24:91-103.
8. Stewart BH, Kugler AR, Thompson PR, et al. A saturable transport mechanism in the intestinal absoprtion of gabapentin is the underlying cause of lack of proportionality between increasing dose and drug levels in plasma. Pharm Res. 1993;10:276-281.
9. Beydoun A, Fischer J, Labar DR, et al. Gabapentin monotherapy, II: a 26-week, double blind, dose-controlled, multicenter study of conversion from polytherapy in outpatients with refractory compfex partial or secondarily generalized seizures. The US Gabapentin Study Group 82/83. Neurology. 1997;49:746-752.
10. Bergey GK, Morris HH, Rosenfeld W, et al. Gabapentin monotherapy, I: An 8-day, double blind, dose-controlled, multicenter study in hospitalized patients with refractory complex partial or secondarily generalized seizures. The US Gabapentin Study Group 88/89. Neurology. 1997;49:739-745.
11. Haig GM, Bockbrader HN, Wesche DL, et al. Single-dose gabapentin pharmacokinetics and safety in healthy infants and children. J Clin Pharmacol. 2001;41:507-514.
12. Quellet D, Bockbrader HN, Wesche DL, et al. Population pharmacokinetics of gabapentin in infants and children. Epilepsy Res. 2001;47:229-241.
13. Gatti G, Ferrari AR, Guerrini R, et al. Plasma gabapentin concentrations in children with epilepsy: influence of age, relationship with dosage, and preliminary observations on correlation with clinical response. Ther Drug Monit. 2003;25:54-60.
14. Boyd RA, Turck D, Abel RB, et al. Effects of age and gender on single-dose pharmacokinetics of gabapentin. Epilepsia. 1999;40:474-479.
15. Eslami M, Stuart JD, Dean RW. Analysis of taurine in blood plasma of epileptic patients using an improved isocratic HPLC method for amino acids. J Liq Chromatogr. 1987;10:977-995.
16. Valdizàn EM, Armijo JA. Relationship between platelet and brain GABA-transaminase inhibition by single and multiple doses of vigabatrin in rats. Epilepsia. 1991;32:735-742.
17. Cohen AF, Land GS, Breimer DD, et al. Lamotrigine a new anticonvulsant: pharmacokinetics in normal humans. Clin Pharmacol Ther. 1987;42:535-541.
18. Herranz JL, Arteaga R, Armijo JA. Three-year efficacy and tolerability of add-on lamotrigine in treatment-resistant epileptic children. Clin Drug Invest. 1996;11:214-223.